Pluxee (ENXTPA:PLX) has been sliding this year, with the share price down nearly 29% year to date, even as revenue and net income continue to edge higher. That disconnect is catching value investors ...
BioMarin Pharmaceutical’s strong rare disease drug portfolio and Amicus acquisition drive a ‘Buy’ rating. Click here to read my latest analysis of BMRN stock.
Regulated information Paris, December 22, 2025 DISCLOSURE FISCAL 2026/07 OF TRANSACTIONS ON TREASURY SHARES Period of: December 15 to December 19, 2025 Issuer: Pluxee N.V. Class of Securities: ...
Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the discovery, development, production and ...
Voting results of the Fiscal 2025 Annual General Meeting of Pluxee Amsterdam-Schiphol, December 17, 2025 // Pluxee N.V. (“Pluxee”) held today its Annual General Meeting of Shareholders, in ...
Despite their popularity, terms such as ‘co-creation’, ‘co-design’ and ‘co-production’ are often misused, risking tokenism and downstream harm. Re-centring on the foundational principles of ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Membership (fee-based) Forbes Technology Council is an invitation-only, fee-based ...
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based ...
Information technology is the design and implementation of computer networks for data processing and communication. This includes designing the hardware for processing information and connecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback